| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.11. | PEGBIO CO-B (02565): FORM OF PROXY FOR USE AT THE 2026 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON THURSDAY, NOVEMBER 26, 2026 | - | HKEx | ||
| PEGBIO Aktie jetzt für 0€ handeln | |||||
| 11.11. | PEGBIO CO-B (02565): NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 11.11. | PEGBIO CO-B (02565): (1) PROPOSED REMOVAL OF AUDITOR (2) PROPOSED APPOINTMENT OF AUDITOR (3) PROPOSED CHANGE IN USE OF PROCEEDS FROM THE GLOBAL OFFERING ... | - | HKEx | ||
| 10.11. | PEGBIO CO-B (02565): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 10.11. | PEGBIO CO-B (02565): COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 06.11. | PEGBIO CO-B (02565): CANCELLATION OF EXTRAORDINARY GENERAL MEETING AND CANCELLATION OF BOOK CLOSURE PERIOD | 3 | HKEx | ||
| 03.11. | PEGBIO CO-B Places Shares at 19% Discount, Net Proceeds Exceed HKD77 million | 2 | AASTOCKS | ||
| 02.11. | PEGBIO CO-B (02565): PLACING OF NEW H SHARES UNDER GENERAL MANDATE | 3 | HKEx | ||
| 23.10. | PEGBIO CO-B (02565): FORM OF PROXY FOR USE AT THE 2026 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON THURSDAY, NOVEMBER 12, 2026 | 1 | HKEx | ||
| 23.10. | PEGBIO CO-B (02565): NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 23.10. | PEGBIO CO-B (02565): (1) PROPOSED REMOVAL OF AUDITOR (2) PROPOSED APPOINTMENT OF AUDITOR (3) PROPOSED CHANGE IN USE OF PROCEEDS FROM THE GLOBAL OFFERING ... | - | HKEx | ||
| 23.09. | PEGBIO CO-B (02565): 2026 INTERIM REPORT | - | HKEx | ||
| 18.09. | PEGBIO CO-B (02565): CHANGE IN USE OF PROCEEDS FROM THE GLOBAL OFFERING | 1 | HKEx | ||
| 18.09. | PEGBIO CO-B (02565): PROPOSED CHANGE OF AUDITOR | - | HKEx | ||
| 02.09. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT JOINT R&D COLLABORATION WITH SN BIOSCIENCE ADVANCING THE LONG-ACTING DEVELOPMENT OF THREE NEXT-GENERATION ... | - | HKEx | ||
| 25.08. | PEGBIO CO-B (02565): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| 13.08. | Lexaria geht Partnerschaft mit PegBio zur Verabreichung von GLP-1-Wirkstoffen ein | 6 | Investing.com Deutsch | ||
| 13.08. | Lexaria enters partnership with PegBio for GLP-1 drug delivery | 3 | Investing.com | ||
| 13.08. | Lexaria Bioscience Corp.: Lexaria Enters a Material Transfer Agreement With PegBio | 469 | ACCESS Newswire | KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into... ► Artikel lesen | |
| 13.08. | PEGBIO CO-B (02565): DATE OF BOARD MEETING | - | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| CG ONCOLOGY | 83,37 | +4,21 % | Guggenheim raises CG Oncology stock price target on trial results | ||
| SUMMIT THERAPEUTICS | 10,680 | +1,71 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| PRAXIS PRECISION MEDICINES | 318,84 | +4,52 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| RECURSION PHARMACEUTICALS | 2,875 | +5,70 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| KYMERA THERAPEUTICS | 120,30 | -1,00 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,850 | +4,00 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| BIONTECH | 75,35 | -1,63 % | BioNTech-Aktie: Totes Kapital? | Die Aktie von BioNTech bleibt trotz des rückläufigen Impfstoffgeschäfts ein spannender Titel am Aktienmarkt. Anleger richten ihren Blick zunehmend auf die milliardenschwere Forschungspipeline im Bereich... ► Artikel lesen | |
| EVOTEC | 2,728 | 0,00 % | Evotec-Aktie: Gewinn- und Umsatzrekord? | Die Aktie des Hamburger Wirkstoffforschers Evotec bleibt ein spannender, aber risikoreicher Titel am deutschen Aktienmarkt. Nach schwierigen Monaten sorgen erste operative Fortschritte, neue Partnerschaften... ► Artikel lesen | |
| ERASCA | 14,140 | +2,61 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| MODERNA | 176,48 | -1,56 % | Moderna nach 300 % Rallye: Droht jetzt eine größere Korrektur? | Seit August verzeichnete Moderna einen deutlichen Kursanstieg, auf den zuletzt eine Zwischenkorrektur folgte. Die bisher intakte Folge höherer Hochs und Tiefs sowie die zuletzt verteidigte 50-Tage-Linie... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,405 | +2,40 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| COGENT BIOSCIENCES | 28,390 | +1,94 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| VOR BIOPHARMA | 18,150 | +1,79 % | Vor Biopharma auf der Jefferies Global Healthcare Conference: Finanzstarker Vorstoß bei Autoimmunerkrankungen | ||
| ABSCI | 8,360 | +2,14 % | Absci auf der Jefferies Global Healthcare Conference: Milliardenmarkt für neuartigen Haarausfall-Wirkstoff im Fokus |